July 9, 2008

Compared with placebo, treatment with laquinimod 0.6 mg per day showed a 40.4% reduction of the baseline adjusted mean cumulative number of Gd+ lesions per scan on the last four scans; treatment with 0.3 mg per day showed no significant effects (3.9 [5.5] vs placebo, p=0.6740). Both doses of laquinimod were well tolerated, with some transient and dose-dependent increases in liver enzymes.

This small study looked at virus DNA in the CSF of people with MS and other neurological diseases. They only found a difference in the presence of HHV-6, but only in a very small number of people with MS. Yet another small, therefore inconclusive, study.